The potential effect of metformin on fibroblast growth factor 21 in type 2 diabetes mellitus (T2DM)

被引：8
|
作者：
Al-kuraishy, Hayder M. [1 ]
Al-Gareeb, Ali I. [1 ]
Saad, Hebatallah M. [2 ]
Batiha, Gaber El-Saber [3 ]
机构：
[1] Al Mustansiriyah Univ, Coll Med, Med Fac, Dept Pharmacol Toxicol & Med, POB 14132, Baghdad, Iraq
[2] Matrouh Univ, Fac Vet Med, Dept Pathol, Marsa Matruh 51744, Egypt
[3] Damanhour Univ, Fac Vet Med, Dept Pharmacol & Therapeut, Damanhour 22511, Egypt
来源：
INFLAMMOPHARMACOLOGY | 2023年 / 31卷 / 04期
关键词：
Fibroblast growth factor 21; T2DM; Metformin; DIFFERENTIATION FACTOR 15; GLUCAGON-LIKE PEPTIDE-1; FGF21; ANALOG; LIPID-METABOLISM; FATTY LIVER; INSULIN; GLUCOSE; EXPRESSION; OBESITY; ACID;
D O I：
10.1007/s10787-023-01255-4
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Fibroblast growth factor 21 (FGF21) is a peptide hormone mainly synthesized and released from the liver. FGF21 acts on FGF21 receptors (FGFRs) and & beta;-Klotho, which is a transmembrane co-receptor. In type 2 diabetes mellitus (T2DM), inflammatory disorders stimulate the release of FGF21 to overcome insulin resistance (IR). FGF21 improves insulin sensitivity and glucose homeostasis. Metformin which is used in the management of T2DM may increase FGF21 expression. Accordingly, the objective of this review was to clarify the metformin effect on FGF21 in T2DM. FGF21 level and expression of FGF2Rs are dysregulated in T2DM due to the development of FGF21 resistance. Metformin stimulates the hepatic expression of FGF21/FGF2Rs by different signaling pathways. Besides, metformin improves the expression of & beta;-Klotho which improves FGF21 sensitivity. In conclusion, metformin advances FGF21 signaling and decreases FGF21 resistance in T2DM, and this might be an innovative mechanism for metformin in the enhancement of glucose homeostasis and metabolic disorders in T2DM patients.
引用
收藏
页码：1751 / 1760
页数：10
相关论文
共 50 条
  • [11] RISK FACTOR CLUSTERING AND THE ECONOMIC MODELING OF TYPE 2 DIABETES MELLITUS (T2DM)
    Willis, M.
    Nilsson, A.
    Asseburg, C.
    [J]. VALUE IN HEALTH, 2019, 22 : S590 - S590
  • [12] Effects of metformin on fibroblast growth factor 21 in patients with type 2 diabetes mellitus: faraway but so close
    Hayder M. Al-kuraishy
    Ali I. Al-Gareeb
    Majid S. Jabir
    Salim Albukhaty
    [J]. The Egyptian Journal of Internal Medicine, 35
  • [13] Effects of metformin on fibroblast growth factor 21 in patients with type 2 diabetes mellitus: faraway but so close
    Al-kuraishy, Hayder M.
    Al-Gareeb, Ali I.
    Jabir, Majid S.
    Albukhaty, Salim
    [J]. EGYPTIAN JOURNAL OF INTERNAL MEDICINE, 2023, 35 (01):
  • [14] Retrospective study of type 2 diabetes mellitus (T2DM) patients not optimally controlled by metformin monotherapy
    He, J.
    Neslusan, C.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A18 - A18
  • [15] Efficacy of metformin alone or in combination with insulin in pediatric patients with type 2 diabetes mellitus (T2DM)
    Weinzimer, SA
    McKnight, WJ
    Murphy, K
    Jawad, AF
    Celona-Jacobs, N
    Haque, A
    Katz, LEL
    [J]. DIABETES, 2001, 50 : A68 - A68
  • [16] THE PREVALENCE OF MICROALBUMINURIA IN CHILDREN WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Yafi, Michael
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD, 2019, 104 : A250 - A250
  • [17] Gut microbiota influence in type 2 diabetes mellitus (T2DM)
    A. L. Cunningham
    J. W. Stephens
    D. A. Harris
    [J]. Gut Pathogens, 13
  • [18] Regional effects of type 2 diabetes mellitus (T2DM) on neurodegeneration
    Moran, C.
    Phan, T. G.
    Beare, R. J.
    Chen, J.
    Blizzard, L.
    Venn, A.
    Greenaway, T.
    Munch, G.
    Forbes, J.
    Pearson, S.
    Srikanth, V
    [J]. INTERNATIONAL JOURNAL OF STROKE, 2012, 7 : 20 - 20
  • [19] Pregnancy outcomes in women with Type 2 diabetes mellitus (T2DM)
    Tan, Z.
    Pang, W. H.
    Todd, D.
    Halliday, M.
    Gill, F.
    Rhoads, M.
    Sathiskumar, P.
    Gallagher, A.
    de Chazal, R.
    Lawrence, I. G.
    [J]. DIABETIC MEDICINE, 2008, 25
  • [20] Renal outcomes in metformin users versus non-metformin users in veterans with type 2 diabetes mellitus (T2DM).
    Gosmanova, E.
    Canada, R. B.
    Mangold, T. A.
    Rawls, W. N.
    Wall, B. M.
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 49 (04) : A42 - A42
12345